Huntington Bancshares Incorporated Hires Three Neurodiverse Teams Fulltime in Technology with CAI Neurodiverse Solutions
April 17, 2024 09:00 ET
|
CAI
CAI today announced that Huntington Bank hired three teams of neurodivergent individuals fulltime through CAI Neurodiverse Solutions.
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
April 11, 2024 16:30 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
March 13, 2024 08:20 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
BlueSprig Pediatrics Sponsors Armani Williams Ahead of the Daytona ARCA 200
February 12, 2024 09:00 ET
|
BlueSprig Pediatrics, Inc.
DAYTONA BEACH, Fla., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Blue Sprig Pediatrics, Inc. (BlueSprig), a leader in Applied Behavior Analysis (ABA) therapy for children diagnosed with Autism Spectrum...
Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements
January 16, 2024 06:00 ET
|
STALICLA
Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the...
Xolv Creates a New Venture to Embark on New Era of Innovation in Behavioral Health
January 03, 2024 16:53 ET
|
Xolv
WALNUT CREEK, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xolv, formerly Catalight’s IT and technology innovation group, proudly announces its transition to a new corporation today as part of a...
NeuroQure Acquires Patents to Detect Autism in Newborns with a Skin Sample
December 13, 2023 09:30 ET
|
NeuroQure
IRVINE, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- NeuroQure, a pioneering biotech startup specializing in gene therapy for neurocognitive disorders, has reached a pivotal milestone in the...
Autism Spectrum Disorder Treatment Market Size to Surpass USD 13.14 Billion by 2030, exhibiting a CAGR of 8.5%
November 27, 2023 06:14 ET
|
Fortune Business Insights
Pune, India, Nov. 27, 2023 (GLOBE NEWSWIRE) -- The autism spectrum disorder treatment market size was valued at USD 6.94 billion in 2022, and it is anticipated to expand from USD 7.41 billion in...
Study: Autistic Children May Need Fewer Hours of Treatment Than Previously Thought
November 21, 2023 13:41 ET
|
Catalight
Walnut Creek, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Each year, tens of thousands of parents and caregivers of children with autism spectrum disorder (ASD) face vital decisions: What kind of...
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
November 20, 2023 08:05 ET
|
Yamo Pharmaceuticals
Yamo Pharmaceuticals LLC has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents with autism spectrum disorder (ASD).